Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Guilin Medical Univ. FXR compound V15
- Development stage
- Unknown
- Lead developer
- Guilin Medical University
01
Overview
Guilin Medical Univ. FXR compound V15: sourced facts only. name: "Herein, we report compound V15, a potent and selective FXR partial agonist featuring a 1-(4-aminophenylacetyl)piperidine scaffold." [PMID:41370973]; target: "Herein, we report compound V15, a potent and selective FXR partial agonist featuring a 1-(4-aminophenylacetyl)piperidine scaffold." [PMID:41370973]; developer: "Guangxi Key Laboratory of Drug Discovery and Optimization, College of Pharmacy, Guilin Medical University, Guilin, 541199, China." [PMID:41370973]; stage: "Significantly, V15 ameliorates high-fat and high-sugar diet-induced MASH in mice by mitigating hepatic steatosis, inflammation, and fibrosis." [PMID:41370973]
02
Targets
FXR (Farnesoid x-activated receptor)
Beyond the preview
Go deeper on Guilin Medical Univ. FXR compound V15.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guilin Medical Univ. FXR compound V15.